{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","estimateComment":"Hazard ratio (HR) \\< 1 favours the cabazitaxel group and \\> 1 favours the mitoxantrone group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5192","paramType":"Cox Proportional Hazard","paramValue":"0.91","statisticalComment":"Log-rank comparisons stratified according to disease measurability and ECOG performance status.","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"Median not reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper confidence interval unevaluable","groupId":"OG001","lowerLimit":"8.1","upperLimit":"NA","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"378"}],"units":"Participants"}],"description":"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score \\& noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.\n\nEvaluation of the PPI \\& analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the intention To Treat (ITT) population. Data from 265 and 279 patients in the cabazitaxel and mitoxantrone groups, respectively, were censored as a results of \\> 2 PPI and/or AS assessments being missed during the same week (unless a complete evaluation of ≥5 values showed pain progression).","reportingStatus":"POSTED","timeFrame":"from baseline up to 104 weeks (study cut-off)","title":"Time to Pain Progression","type":"SECONDARY","unitOfMeasure":"Months"}